Project Grant R15DA056843
Award Date
8/1/22
Completion Date
7/31/25
Dollars Obligated
$760K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
West Virginia, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to generate synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel multivalent compounds for treating substance use disorders (SUDs). The $399,483 award, effective May 15, 2025 through April 30, 2026, supports a 3-part research plan. In Aim 1, the recipient, Jillion Therapeutics Inc., will screen a DEL...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 "Drug Use and Addiction Research Programs," provides $400,000 in funding to Iontx Inc. to advance the development of a novel small-molecule compound that modulates the FGF13/NAV1.6 protein complex to normalize nucleus accumbens activity for the treatment of Cocaine Use Disorder (CUD). The primary objectives are to conduct structure-activity relationship (SAR) analysis and optimization...
This federal Project Grant award of $1,717,200 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons (SST-INs) in the prefrontal cortex as potential targets for developing breakthrough treatments for opioid use disorder (OUD). The research seeks to take an unbiased transcriptomics approach to identify GPCR...
The federal Cooperative Agreement award UG3DA059278, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop SBS-226, a novel mu-opioid receptor (MOR) agonist and delta-opioid receptor (DOR) antagonist, for the treatment of opioid use disorder (OUD). The $11,872,077 project will support comprehensive IND-enabling development and a Phase 1 clinical trial for SBS-226, a non-addictive compound demonstrated to have...
This $405,230 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to advance NR4A1 as a novel target for the treatment of cocaine use disorder. The award period runs from January 15, 2025 to December 31, 2025. The key products and services to be delivered through this funding include: 1) Lead identification through synthesis and screening of cytosporone B (CSNB) derivatives that activate human and mouse...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $275,253 in funding to Epivario Inc. to develop a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grant supports research focused on inhibiting the metabolic enzyme ACSS2, which is involved in the neuroplasticity processes underlying drug-related memory consolidation and addiction behaviors. Epivario...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to discover novel small molecule therapeutics for safe and effective treatment of opioid use disorder (OUD). The $798,828 grant will fund the development of an AI-powered drug discovery platform called M3.AI, which will integrate target-based and phenotype-based approaches to identify multi-cell type and multi-target polypharmacological...
This $1,447,919 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research into the development of cocaine addiction and interventions targeting the "need-state" hypothesis. The project aims to use an animal model to identify early markers of addiction vulnerability, measure associated neural activation patterns, and evaluate whether treatment with a GLP-1 receptor agonist can reverse these...
This $314,225 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to explore the unique neurobehavioral profile of sequential opioid-stimulant polysubstance use disorders. The study aims to: 1) Define the behavioral patterns of dual opioid-methamphetamine use disorders in a rodent model, and 2) Map neural activation patterns in the cortico-basal ganglia-thalamic circuit in response to opioid...
This $397,829 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of an AI-based platform to discover new therapeutic options for substance use disorders (SUDs). The key objectives of the project are to: 1) create curated training datasets and machine learning models to accelerate drug discovery tasks, 2) identify mechanistic targets related to glucagon-like peptide 1 (GLP-1) receptor...